Table 2.
Previous Therapy and Responses in Venetoclax Trials
| Venetoclax Phase150 | Venetoclax/Dex52 | Venetoclax/Bortezomib | ||||
|---|---|---|---|---|---|---|
| Non t(11;14) | t(11;14) | Phase 1 | Phase 2 | Phase 156 | Phase 357 | |
| Patients | 36 | 30 | 20 | 31 | 66 | 194 |
| Median lines | 5 (1–15) | 5 (1–15) | 3 | 5 | 3 (1–13) | 1–3 |
| Bortezomib refractory | 67% | 73% | 65% (PI) | 87% (PI) | 39% | 0% |
| Lenalidomide refractory | 78% | 77% | 90% (imid) | 87% (imid) | 53% | 20% |
| Carfilzomib refractory | 25% | 37% | ||||
| Pomalidomide refractory | 50% | 70% | ||||
| Daratumumab refractory | 20% | 87% | ||||
| ASCT | 81% | 70% | 85% | 58% | 59% | 60% |
| ORR | 6% | 40% | 60% | 48% | 67% | 82% |
| CR | 3% | 14% | 5% | 7% | 5% | 27% |
| ≥VGPR | 6% | 27% | 30% | 36% | 20% | 59% |
| OS (mo) | NE | |||||
| PFS (mo) | 22.4 | |||||
| DOR (mo) | NE | 9.7 | 12.4 | NE | 9.7 | NE |
| TTP (mo) | 12.4 | 10.8 | 9.5 | |||
Abbreviations: Dex, dexamethasone; ASCT, autologous stem cell transplant; ORR, overall response rate; CR, complete response; VGPR, very good partial response; OS, overall survival; PFS, progression-free survival; DOR, duration of response; TTP, time to progression; Mo, months.